Helex

📍 New York, United States🗓 Founded 2021👥 28 employees💰 Last funded Dec 2025
Biotechnology🌐 helex.bio
Website LinkedIn
Helex is taking the promise of non-viral targeted delivery and genome editing to the kidney, developing first-in-class genetic medicines for renal indications. Helex combines its proprietary kidney tropic lipid nanoparticle delivery system with the Epic-Cure(TM) 3D genome-based drug designer platform to create a robust renal franchise of precise and scalable therapeutics. Our lead asset is a mutation-agnostic, potential one-and-done therapy for Autosomal Dominant Polycystic Kidney Disease that impacts over 4 million people worldwide.
4
Total investors
1
Early stage
3
Mid stage
0
Late stage
2021
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
India
3
United States
1
Investor activity2021–2025 · investors recorded per year
2021120253
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Helex?
Helex has 4 investors on record on gritt.io, including 1 early-stage backers, 3 mid-stage.
When did Helex last raise funding?
The most recent investment in Helex recorded on gritt.io was in December 2025.
When was Helex founded?
Helex was founded in 2021.
What industry is Helex in?
Helex operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Helex based?
Helex is headquartered in New York, United States.